The CLL market is known to be significantly bigger than the Acute lymphocytic leukemia ('ALL') market and CLL is the most frequent Leukemia occurring in Western countries. The CLL market is being driven by increasing incidence primarily due to aging populations along with the use of combination therapies instead of monotherapies or chemoimmunotherapy regimens. The Company will also be able to apply the same platform technology to develop it's CAR T-cell therapy for Solid tumors such as Ovarian and Lung cancers, which provide further enormous opportunities for the Company. The CLL CAR T-cell therapy market is currently not dominated by any single player, compared to the CD-19 CAR T-cell therapy market which has become extremely competitive, dominated by big pharma corporations.
The Company, has recently strengthened its board to focus on it's own developed technology and is looking forward to obtaining its own patents where there are currently no restrictions, which is in contrast to CD-19 Car T therapy. The previous work that the Company undertook in the CD-19 CAR T field has been invaluable and given the Company enhanced technical expertise and knowhow for the development of it's own new CAR T-cell therapy in addition to its existing Biosimilar development technologies.
Dr.
About Biocure
Biocure is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer. Biocure is in the process of pre-clinical trials of five major biosimilar products in
ON BEHALF OF THE BOARD OF DIRECTORS
/S/ 'SANG MOK LEE'
CEO and Director
Contact:
Telephone: 604-609-7146
E: info@biocuretech.com
Certain statements in this news release, which are not historical in nature, constitute 'forward looking statements' within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company's proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management's current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the 'CSE') nor the
(C) 2021 Electronic News Publishing, source